Nikunj Satani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9052208/publications.pdf

Version: 2024-02-01

29	2,420	516710	610901
papers	citations	16 h-index	24 g-index

34	34	34	5317
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell, 2017, 32, 42-56.e6.	16.8	1,282
2	Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature, 2017, 542, 119-123.	27.8	209
3	The intricate mechanisms of neurodegeneration in prion diseases. Trends in Molecular Medicine, 2011, 17, 14-24.	6.7	119
4	HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nature Communications, 2017, 8, 451.	12.8	107
5	SF2312 is a natural phosphonate inhibitor of enolase. Nature Chemical Biology, 2016, 12, 1053-1058.	8.0	90
6	Stem Cells as an Emerging Paradigm in Stroke 4. Stroke, 2019, 50, 3299-3306.	2.0	68
7	The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. Journal of the National Cancer Institute, 2018, 110, 777-786.	6.3	58
8	An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nature Metabolism, 2020, 2, 1413-1426.	11.9	49
9	Ongoing Secondary Degeneration of the Limbic System in Patients With Ischemic Stroke: A Longitudinal MRI Study. Frontiers in Neurology, 2019, 10, 154.	2.4	35
10	ENOblock Does Not Inhibit the Activity of the Glycolytic Enzyme Enolase. PLoS ONE, 2016, 11, e0168739.	2.5	34
11	World-Wide Efficacy of Bone Marrow Derived Mesenchymal Stromal Cells in Preclinical Ischemic Stroke Models: Systematic Review and Meta-Analysis. Frontiers in Neurology, 2019, 10, 405.	2.4	29
12	Protective Effects of Autologous Bone Marrow Mononuclear Cells After Administering t-PA in an Embolic Stroke Model. Translational Stroke Research, 2018, 9, 135-145.	4.2	26
13	Mesenchymal Stem Cell Derived Extracellular Vesicles for Repairing the Neurovascular Unit after Ischemic Stroke. Cells, 2021, 10, 767.	4.1	25
14	Is Immunomodulation a Principal Mechanism Underlying How Cell-Based Therapies Enhance Stroke Recovery?. Neurotherapeutics, 2016, 13, 775-782.	4.4	23
15	Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine. Nature Communications, 2021, 12, 4228.	12.8	21
16	Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunology, Immunotherapy, 2021, 70, 1101-1113.	4.2	18
17	A metaâ€analysis of the global impact of the COVIDâ€19 pandemic on stroke care & the Houston Experience. Annals of Clinical and Translational Neurology, 2021, 8, 929-937.	3.7	16
18	Cryopreservation of Bone Marrow Mononuclear Cells Alters Their Viability and Subpopulation Composition but Not Their Treatment Effects in a Rodent Stroke Model. Stem Cells International, 2016, 2016, 1-7.	2.5	11

#	Article	IF	Citations
19	Mesenchymal stromal cell secretomes are modulated by suspension time, delivery vehicle, passage through catheter, and exposure to adjuvants. Cytotherapy, 2017, 19, 36-46.	0.7	11
20	The 3S Enantiomer Drives Enolase Inhibitory Activity in SF2312 and Its Analogues. Molecules, 2019, 24, 2510.	3.8	10
21	Aspirin in stroke patients modifies the immunomodulatory interactions of marrow stromal cells and monocytes. Brain Research, 2019, 1720, 146298.	2.2	10
22	Medications for Hypertension Change the Secretome Profile from Marrow Stromal Cells and Peripheral Blood Monocytes. Stem Cells International, 2020, 2020, 1-28.	2.5	3
23	A Combination of Atorvastatin and Aspirin Enhances the Pro-Regenerative Interactions of Marrow Stromal Cells and Stroke-Derived Monocytes In Vitro. Frontiers in Pharmacology, 2021, 12, 589418.	3.5	3
24	Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity. , 2013, 1, .		0
25	MTR-19A MACROPHAGE-/MICROGLIAL-RICH TUMOR MICROENVIRONMENT MIMICS PRONEURAL TO MESENCHYMAL TRANSITION IN GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v128.3-v128.	1.2	0
26	Enhancing Stroke Recovery With Cellular Therapies. , 2022, , 900-911.e5.		0
27	Abstract 3837: Passenger deletion of ENO1 as a collateral lethality target in cancer. , 2016, , .		0
28	Abstract 4242: Rhodamine esters as fluorescent tumor painting agents for glioblastoma. , 2016, , .		0
29	Abstract 2831: Collateral lethality: A new target for personalized oncology. , 2018, , .		0